More recently, we demonstrated that addition of dual ICB with programmed death ligand 1 (PD-L1) and lymphocyte activation gene-3 (Lag-3) monoclonal antibodies (mAbs) to the Tag-Th1 cell and 2 Gy TBI treatment was applicable to control tumor burden even in late-stage RIP1-Tag2 mice with heavily progressed and metastasized carcimonas 8, 9; but the role of TBI in the low-dose of 2 Gy remained completely unclear. The gene discussed is LAG3; the disease is neoplasm.